share_log

Preclinical Trial Results Confirm Targeting Type 2 Cannabinoid Receptors Helps Relieve Sepsis-Related Condition

Benzinga Real-time News ·  Aug 10, 2022 10:40

Tetra Bio-Pharma Inc.(OTCQB:TBPMF) (TSX:TBP) (FRA:JAM1) revealedpositive preclinical results from live SARS-CoV-2 virus infection studiesas well as a septic lung model, carried out by independent researchers.

These studies explored the potential ofARDS-003 to increase survival metrics following SARS-CoV-2 infection in the humanized ACE2 mouse model. Secondary outcomes evaluated ARDS-003 against an antiviral drug, a clinical standard of care therapeutic used for patients with COVID, in SARS-CoV-2 infected animals. Results indicate that compared to placebo, ARDS-003 dose dependently reduced signs of morbidity and mortality, including respiratory distress. ARDS-003 also outperformed the antiviral drug...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment